[go: up one dir, main page]

AU2000265516A1 - Compositions and methods for inhibiting islet dysfunction and autoimmune disorders - Google Patents

Compositions and methods for inhibiting islet dysfunction and autoimmune disorders

Info

Publication number
AU2000265516A1
AU2000265516A1 AU2000265516A AU6551600A AU2000265516A1 AU 2000265516 A1 AU2000265516 A1 AU 2000265516A1 AU 2000265516 A AU2000265516 A AU 2000265516A AU 6551600 A AU6551600 A AU 6551600A AU 2000265516 A1 AU2000265516 A1 AU 2000265516A1
Authority
AU
Australia
Prior art keywords
compositions
methods
autoimmune disorders
islet dysfunction
inhibiting islet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2000265516A
Other languages
English (en)
Inventor
David J. Hill
Claude Remacle
Brigitte Reusens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LAWSON HEALTH RESEARCH INSTITUTE
Universite Catholique de Louvain UCL
Original Assignee
LAWSON HEALTH RES INST
Universite Catholique de Louvain UCL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LAWSON HEALTH RES INST, Universite Catholique de Louvain UCL filed Critical LAWSON HEALTH RES INST
Publication of AU2000265516A1 publication Critical patent/AU2000265516A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2000265516A 2000-08-11 2000-08-11 Compositions and methods for inhibiting islet dysfunction and autoimmune disorders Abandoned AU2000265516A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CA2000/000925 WO2002013813A1 (fr) 2000-08-11 2000-08-11 Inhibition du dysfonctionnement des îlots de langerhans et de troubles autoimmunes, et compositions à cet effet

Publications (1)

Publication Number Publication Date
AU2000265516A1 true AU2000265516A1 (en) 2002-02-25

Family

ID=4143075

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2000265516A Abandoned AU2000265516A1 (en) 2000-08-11 2000-08-11 Compositions and methods for inhibiting islet dysfunction and autoimmune disorders
AU2001283739A Abandoned AU2001283739A1 (en) 2000-08-11 2001-08-09 Compositions and methods for inhibiting islet dysfunction and autoimmune disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2001283739A Abandoned AU2001283739A1 (en) 2000-08-11 2001-08-09 Compositions and methods for inhibiting islet dysfunction and autoimmune disorders

Country Status (5)

Country Link
US (1) US20030180345A1 (fr)
EP (1) EP1309321A1 (fr)
AU (2) AU2000265516A1 (fr)
CA (1) CA2386985A1 (fr)
WO (2) WO2002013813A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1537865A1 (fr) * 2003-12-03 2005-06-08 Franz-Peter Dr. Liebel Utilisation de composés contenant du soufre et d'enzymes protéolytiques pour la prévention et la thérapie du Diabètes mellitus type II déficitaire de UDP-Glucuronosyltransférase 1
EP1537864A1 (fr) * 2003-12-03 2005-06-08 Franz-Peter Dr. Liebel Utilisation d'acides aminés et de composés contenant du soufre pour la prévention et la thérapie du Diabetes mellitus type II déficitaire de UDP Glucuronosyltransférase 1
EP1715881A1 (fr) * 2004-02-12 2006-11-02 Campina Nederland Holding B.V. Peptides riches en cysteine destines a ameliorer l'homeostasie des thiols
IL160420A0 (en) * 2004-02-16 2004-07-25 Yissum Res Dev Co Treating or preventing diabetes with cannabidiol
GB0525504D0 (en) 2005-12-14 2006-01-25 Bristol Myers Squibb Co Antimicrobial composition
US20080026378A1 (en) 2006-07-28 2008-01-31 Gian Franco Bottazzo Prediction and prophylactic treatment of type 1 diabetes
CA2691147C (fr) * 2006-07-28 2018-07-10 Mattia Locatelli Prediction et traitement prophylactique du diabete de type 1
GB201020236D0 (en) 2010-11-30 2011-01-12 Convatec Technologies Inc A composition for detecting biofilms on viable tissues
CN105008611A (zh) 2012-12-20 2015-10-28 康沃特克科技公司 化学改性的纤维素纤维的处理

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5334617A (en) * 1984-03-19 1994-08-02 The Rockefeller University Amino acids useful as inhibitors of the advanced glycosylation of proteins
US4751085A (en) * 1984-08-29 1988-06-14 Gaull Gerald E Human nutritional compositions containing taurine and vitamins and/or minerals
SE8704542D0 (sv) * 1987-11-19 1987-11-19 Draco Ab New derivatives of cysteine
DE326326T1 (de) * 1988-01-25 1990-02-08 Santen Pharmaceutical Co., Ltd, Osaka Cysteinderivate.
US6294520B1 (en) * 1989-03-27 2001-09-25 Albert T. Naito Material for passage through the blood-brain barrier
US4980168A (en) * 1989-10-13 1990-12-25 Natrol, Inc. Dietary supplement for children
AU641529B2 (en) * 1990-07-30 1993-09-23 Bloomfield D.A. Zwitterionic compounds and their N-halo derivatives for use in the treatment of clinical conditions
US5132113A (en) * 1990-10-26 1992-07-21 Maurizio Luca Nutritional composition containing essential amino acids
US5602150A (en) * 1992-10-02 1997-02-11 Research Foundation For Mental Hygiene, Inc. Treatment of central nervous system disorders associated with psychotic behavior and dementia with a combination of neuroleptic drugs and taurine, or derivatives thereof, to prevent the development of tardive dyskinesia
RU2054936C1 (ru) * 1994-04-07 1996-02-27 Елизарова Евгения Павловна Мембраностабилизирующее средство для лечения больных с инсулинзависимым и инсулиннезависимым сахарным диабетом
SE9601395D0 (sv) * 1996-04-12 1996-04-12 Dieter Haeussinger New therapeutic treatment 1
GB2312621B (en) * 1996-05-02 1998-03-11 Pharma Nord Uk Limited Anti-oxidant medicament
EP0891719A1 (fr) * 1997-07-14 1999-01-20 N.V. Nutricia Composition dietique contenant de la methionine
US6171856B1 (en) * 1997-07-30 2001-01-09 Board Of Regents, The University Of Texas System Methods and compositions relating to no-mediated cytotoxicity
US6136339A (en) * 1998-08-21 2000-10-24 Gardiner; Paul T. Food supplements and methods comprising lipoic acid and creatine
JP2000119179A (ja) * 1998-10-09 2000-04-25 Taisho Pharmaceut Co Ltd インスリン非依存性糖尿病の合併症の予防薬
IT1312377B1 (it) * 1999-03-05 2002-04-15 Uni Ci S R L Composizioni a base di acido tiottico, cisteina e/o n-acetil cisteinada utilizzarsi in preparazioni farmaceutiche, dietetiche e cosmetiche
WO2000072854A1 (fr) * 1999-06-02 2000-12-07 Ashni Naturaceuticals, Inc. Complement alimentaire contenant un sulfate vanadyl, un acide alpha-lipoique et une taurine

Also Published As

Publication number Publication date
WO2002013814A1 (fr) 2002-02-21
WO2002013813A1 (fr) 2002-02-21
EP1309321A1 (fr) 2003-05-14
AU2001283739A1 (en) 2002-02-25
CA2386985A1 (fr) 2002-02-21
US20030180345A1 (en) 2003-09-25

Similar Documents

Publication Publication Date Title
AU2001253255A1 (en) Compositions and methods for inhibiting gene expression
GB2351285B (en) Corrosion inhibiting compositions and methods
AU2002346651A1 (en) Endorepellin compositions and methods for inhibiting angiogenesis
AU2001250821A1 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
IL151518A0 (en) Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one and use thereof for inhibiting hormone-sensitive lipase
AU2002225894A1 (en) Methods and compositions for the control of coccidiosis
AU2001286750A1 (en) Compositions and methods for exon profiling
AU2002222627A1 (en) Tak1 inhibitors
AU2000265516A1 (en) Compositions and methods for inhibiting islet dysfunction and autoimmune disorders
AU2001244562A1 (en) Neovascularization inhibitors
AU2002239258A1 (en) Houttuyninum compositions and methods for inhibiting the activity of erbb-2 based thereon
AU2001283226A1 (en) Methods and compositions for inhibiting rad51
AU2001264522A1 (en) Methods and compositions for the prevention of myopia
AU2001233086A1 (en) Ceramidase compositions and methods based thereon
AU2002351200A1 (en) Compositions and methods for inhibiting prenyltransferases
AU5632300A (en) Methods of inhibiting muscle atrophy
AU7330600A (en) Methods and compositions for the chromosomal integration of heterologous sequences
AU2001251111A1 (en) Lubricant and flushing compositions
AU3198300A (en) Non-spreading pestivirus
AU2001264650A1 (en) Adrenal dysfunction
AU2002228911A1 (en) Methods for inhibiting pain
AU6733500A (en) Agents for ameliorating erectile dysfunction
AU1623801A (en) Opioid metallopeptide compositions and methods
AU2001295689A1 (en) Compositions and methods for regulating the nervous system
AU2986800A (en) Methods of inhibiting the hgf-met-upa-plasmin network